Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 18/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792573 | 0.90 | TGFBR1 (0.45) | CDK4CDK2TGFBR1KDRMAPK14 | |
| SCHEMBL5789426 | 0.88 | NPC1 (0.47) | TGFBR1KDRMAPK14SMN1; SMN2 | |
| SCHEMBL5791351 | 0.87 | TGFBR1 (0.44) | CDK4CDK2TGFBR1KDRMAPK14 | |
| SCHEMBL5787144 | 0.86 | TGFBR1 (0.60) | TGFBR1KDRMAPK14RIPK2 | |
| SCHEMBL6372080 | 0.86 | TGFBR1 (0.51) | CDK4CDK2TGFBR1KDRMAPK14 | |
| SCHEMBL6364773 | 0.84 | TGFBR1 (0.42) | TGFBR1KDRMAPK14GAAMAPT | |
| SCHEMBL5787031 | 0.84 | GAA (0.48) | TGFBR1KDRMAPK14GAAMAPT | |
| SCHEMBL5791222 | 0.84 | TGFBR1 (0.40) | CDK4CDK2TGFBR1KDRMAPK14 | |
| SCHEMBL5786598 | 0.84 | CCNE1 (0.49) | CDK4CDK2TGFBR1KDRMAPK14 | |
| SCHEMBL5789350 | 0.83 | CDK2 (0.44) | CDK4CDK2TGFBR1KDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543003-B1 | IMIDAZO¬1,2-A|PYRIDINES | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | DODIC NERINA | 2005-11-03 | — | — | US | disclosed |
| US-20050234029-A1 | Compounds | DODIC NERINA | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | SMAD2, SMAD3, ALK | CDK4 262/4885CDK2 98/4885TGFBR1 7/4885 |
| US-20050234029-A1 | Compounds | SMAD3, SMAD2, ACVR1 | CDK4 174/4885CDK2 47/4885TGFBR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.